Gribero (Dabigatran Etexilate)

Gribero is indicated for several anticoagulation purposes in adult patients.

• Prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation.
• Treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Secondary prevention of recurrent DVT and PE after initial therapy.
• Long‑term anticoagulation to reduce the risk of thrombotic events in patients with a history of venous thromboembolism.
• Use in patients who are unable to receive vitamin K antagonist therapy due to contraindications or monitoring challenges.
• Consideration for patients requiring a predictable anticoagulant effect without routine laboratory monitoring.

The safety profile of Gribero includes a range of observed adverse events, which are categorized by frequency and severity.

Common

• Dyspepsia or stomach discomfort.
• Minor bleeding such as gum bleeding, nosebleeds, or easy bruising.
• Diarrhea or abdominal pain.
• Headache or dizziness.
• Nausea or vomiting.
• Fatigue or general weakness.
• Insomnia or sleep disturbances.
• Mild rash or skin irritation.

Serious

• Major bleeding events, including intracranial hemorrhage.
• Gastrointestinal bleeding requiring medical attention.
• Allergic reactions such as rash, itching, or swelling.
• Elevated liver enzymes indicating possible hepatic involvement.
• Rare thrombotic events such as myocardial infarction.
• Severe allergic reaction (anaphylaxis).
• Kidney function decline in patients with pre-existing renal impairment.

When prescribing Gribero, clinicians consider several precautionary measures to ensure safe use and to minimize risk.

• Assess renal function before initiation and periodically during therapy.
• Use caution in patients with a history of gastrointestinal bleeding or ulcer disease.
• Avoid use in patients with active major bleeding or severe uncontrolled hypertension.
• Adjust dose or consider alternative therapy in elderly patients or those with low body weight.
• Counsel patients on the importance of adherence and the risks of missed doses.
• Evaluate liver function, especially in patients with known hepatic disease.
• Review concomitant use of antiplatelet agents or non‑steroidal anti‑inflammatory drugs (NSAIDs).

Gribero may interact with other medicines, affecting its anticoagulant effect or increasing bleeding risk.

Avoid

• Strong P-glycoprotein (P-gp) inhibitors such as ketoconazole, itraconazole, and ritonavir.
• Other anticoagulants (e.g., warfarin, heparin) or antiplatelet agents (e.g., clopidogrel, aspirin) when combined without careful monitoring.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) at high doses that significantly raise bleeding risk.

Use with caution

• Moderate P-gp inhibitors like amiodarone, verapamil, and quinidine.
• Dual antiplatelet therapy (e.g., aspirin plus clopidogrel) in patients with high thrombotic risk.
• Renal impairment; dose adjustment may be needed.
• Concomitant use of selective serotonin reuptake inhibitors (SSRIs) or selective serotonin‑norepinephrine reuptake inhibitors (SNRIs) which can increase bleeding.